SharpLink has deployed $400 million of its Ether (ETH) treasury across two staking protocols, Ether.fi and Lido. This includes a previously announced $200 million allocation through Lido, where wrapped staked Ether (wstETH) is held with Anchorage Digital for custody. The deployment activates SharpLink's plan to earn staking rewards by leveraging these decentralized finance platforms, signaling confidence in ETH staking as a yield strategy. This move could influence other digital asset holders to consider staking for passive income.
SharpLink's $400 million Ether deployment is notable market context. For readers following cryptocurrency, here is Pluang's market snapshot as of Oct 20, 2026 06:02 WIB: out of 50 major cryptocurrencies priced on Pluang, 42 rose and 7 fell today. Among movers, CRV (Curve DAO Token) rose 7.85% to Rp6.647 with a typical hold time of 62 days and Pluang order activity at 99% Sell / 1% Buy; DOT (Polkadot) increased 4.90% to Rp20.661 with a typical hold time of 121 days and order activity 83% Sell / 17% Buy; ATOM (Cosmos) gained 4.80% to Rp31.388 with a typical hold time of 61 days and order activity 24% Sell / 76% Buy.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
